StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Each factor shows GRDN's percentile within the scored universe — observational ranking, not a recommendation.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-19 | $35.74 | $36.28 | +1.51% | 0.4M |
| 05-20 | $36.46 | $37.63 | +3.21% | 0.4M |
| 05-21 | $37.16 | $38.37 | +3.26% | 0.6M |
| 05-22 | $38.30 | $38.48 | +0.47% | 0.3M |
| 05-26 | $37.84 | $38.59 | +1.98% | 0.4M |
Aggregate of 12 sell-side ratings as of 2026-05-01. Stonvex does not endorse these ratings.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Earnings (▲ beat / ▼ miss) and ex-dividend dates plotted on the price line. Educational — proximity does not establish causation.
Next report date, year-over-year trend, and recent quarter history.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Past 1 reported quarters: EPS surprise vs estimate and the day-after-release stock reaction. Past performance does not predict future moves.
Sources: Finnhub earnings calendar + Polygon daily aggregates. Reaction direction can diverge from EPS surprise (guidance, macro, or sector flow can dominate the next-day print).
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q3 2026 (Est.) Expected 2026-08-10 | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|---|
Revenue | $346.78M | $336.60M | $1.45B | $1.05B | $673.64M |
Operating Income | Not available | $17.68M | $72.70M | $41.94M | $25.59M |
Net Income | Not available | $13.29M | $49.22M | $28.30M | $9.03M |
EPS (Diluted) | $0.27 | Not available | Not available | Not available | Not available |
Total Assets | Not available | $426.94M | $412.66M | $390.04M | $356.33M |
Total Liabilities | Not available | $194.52M | $194.73M | $194.54M | $176.66M |
Cash & Equivalents | Not available | $64.89M | $65.62M | $36.49M | $18.82M |
Free Cash Flow OCF − CapEx | Not available | Not available | $86.84M | $52.73M | $28.57M |
Shares Outstanding | Not available | Not available | Not available | Not available | Not available |
Guardian Pharmacy Services Inc is a pharmacy services company providing technology-enabled services to help residents of long-term health care facilities (LTCFs) adhere to appropriate drug regimens, reducing the cost of care and improving clinical outcomes. The Company provides high-touch clinical, drug dispensing, and administration services tailored to residents in assisted living facilities, behavioral health facilities, and group homes, while also serving residents in all types of LTCFs. It partners with residents, LTCFs, and health plan payors to help reduce errors in drug administration, manage drug regimens, and improve adherence. The Company derives its revenue mainly from the sale of pharmaceutical and medical products.